Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

Chalmers University of Technology spin out takes a different route to cancer biomarker identification

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Start-up Spotlight

Diagnostic tools have rarely had such concerted attention as during COVID-19. And science advances have been moving modern diagnostic techniques, such as circulating tumor DNA biomarkers, epigenetic markers, DNA methylation and RNA screening, up the agenda.

But those technologies are not particularly sensitive to the early stages of cancer, said Elypta CEO Karl Bergman. The company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

Execs On The Move: July 7–11, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.